All
Prostate Cancer Foundation's Robust Collection of New Patient Resources Now Available
May 13th 2019The Prostate Cancer Foundation announced the newly revised 2019 Prostate Cancer Patient Guide, a comprehensive resource for diagnosis, treatment, side effects, survivorship, and risk factors for patients and families with a history of prostate cancer.
Opdivo Plus Radiation Fails to Prolong Survival in Subtype of Glioblastoma
May 9th 2019The phase 3 CheckMate 498 trial, designed to compare Opdivo with Temodal for the treatment of patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme failed to meet its primary endpoint of increasing overall survival.
FDA Approves Tibsovo for Frontline IDH1-Mutant Acute Myeloid Leukemia
May 2nd 2019The FDA has approved a supplemental new drug application for Tibsovo as a single agent for the first-line treatment of adult patients with IDH1-mutant acute myeloid leukemia who are 75 years and older or are ineligible to receive intensive chemotherapy.